David Amsellem
Stock Analyst at Piper Sandler
(4.83)
# 78
Out of 5,090 analysts
163
Total ratings
66.67%
Success rate
25.92%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $3.81 | +136.22% | 1 | Nov 25, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $118 → $157 | $181.82 | -13.65% | 3 | Nov 21, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $340.33 | +11.95% | 6 | Nov 14, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $6.48 | +23.48% | 2 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Neutral | $6 → $8 | $6.72 | +19.14% | 6 | Nov 7, 2025 | |
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $228.71 | +26.36% | 2 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $34.74 | +18.04% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $11.89 | +9.34% | 5 | Oct 31, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $175 → $179 | $153.75 | +16.42% | 12 | Oct 29, 2025 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $45 | $29.30 | +53.61% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $44.86 | +44.90% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $27.01 | -7.44% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $85.15 | +42.10% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $7.14 | +152.10% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $47.54 | -22.16% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $176 → $147 | $166.39 | -11.65% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $51.95 | +25.12% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.73 | -6.76% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $28.41 | +5.60% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $21.36 | -39.12% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $82.13 | -17.20% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.38 | -59.35% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $23.97 | +75.22% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.71 | +466.04% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $148.41 | -23.86% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $38.25 | +9.80% | 3 | Oct 16, 2023 |
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.81
Upside: +136.22%
Biogen
Nov 21, 2025
Reiterates: Neutral
Price Target: $118 → $157
Current: $181.82
Upside: -13.65%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $340.33
Upside: +11.95%
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $6.48
Upside: +23.48%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.72
Upside: +19.14%
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $228.71
Upside: +26.36%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $34.74
Upside: +18.04%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $11.89
Upside: +9.34%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $153.75
Upside: +16.42%
Alkermes
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $29.30
Upside: +53.61%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $44.86
Upside: +44.90%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $27.01
Upside: -7.44%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $85.15
Upside: +42.10%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $7.14
Upside: +152.10%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $47.54
Upside: -22.16%
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $166.39
Upside: -11.65%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $51.95
Upside: +25.12%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.73
Upside: -6.76%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $28.41
Upside: +5.60%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $21.36
Upside: -39.12%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $82.13
Upside: -17.20%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.38
Upside: -59.35%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $23.97
Upside: +75.22%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.71
Upside: +466.04%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $148.41
Upside: -23.86%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $38.25
Upside: +9.80%